GAITHERSBURG, Md. and VIENNA, June 19 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) announced that its Chief Scientific Officer, Gregory Glenn, M.D., and Alexander Von Gabain, Ph. D., the Chief Scientific Officer of Intercell AG (VSE: ICLL), will speak today at the Biotechnology Industry Organization's International Convention at a breakout session titled "Breakthrough Technologies, Burgeoning Business."
The session will begin at 4 p.m. in room 30A of the San Diego Convention Center.
As previously announced, Iomai and Intercell AG have entered into an agreement whereby Iomai has agreed to be acquired by Intercell AG.
About Iomai Cooperation
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.
Iomai announced on May 12 that it has entered into an agreement with Intercell AG in which Intercell will acquire Iomai for $6.60 a share.
About Intercell AG
Intercell AG is a growing biotechn
|SOURCE Iomai Corporation|
Copyright©2008 PR Newswire.
All rights reserved